908 Devices Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. The company sells handheld and desktop mass spectrometry devices, consumables and services for government, life sciences and related markets. Figures below are in U.S. dollars; financial statement amounts are in millions unless stated otherwise.
Financial performance and position
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $11.1 | $8.3 | $19.4 | $13.8 |
| Gross profit | $6.6 | $4.4 | $10.8 | $7.3 |
| Gross margin | 60% | 53% | 55% | 53% |
| Operating expenses | $15.0 | $11.8 | $28.7 | $20.6 |
| Operating loss | $(8.4) | $(7.5) | $(17.9) | $(13.3) |
| Net loss | $(8.1) | $(7.4) | $(17.5) | $(13.5) |
| Net loss per share, basic and diluted | $(0.26) | $(0.27) | $(0.56) | $(0.49) |
- Q2 revenue rose 34%; six-month revenue rose 40%. Product and service revenue drove growth, increasing 34% in Q2 and 40% for the half year. Six-month device sales increased 32%, while consumables and service revenue increased 68%.
- Government customers were the largest product-and-service market: $11.7 million for the first half, versus $6.7 million from pharmaceutical and biotechnology customers.
- Operating costs grew faster than revenue in absolute terms. Higher R&D and selling, general and administrative expenses contributed to larger operating and net losses. Six-month SG&A included higher staffing, stock compensation, travel and marketing costs; the prior-year period included a $1.7 million bad-debt provision.
- Cash and cash equivalents were $213.0 million at June 30, down from $224.1 million at December 31, 2021. Six-month operating cash use was $10.9 million, versus $16.9 million a year earlier; capital expenditures used $0.7 million. Financing provided $0.6 million net, including $30 million drawn and repaid under the revolver during the period.
- Long-term debt was $15.0 million, unchanged from year-end. The company had a $25 million revolving credit facility, maturing March 2024, and reported compliance with its covenants, including a $10 million minimum unrestricted-cash covenant. Current assets were $238.7 million and current liabilities $15.4 million.
- Accumulated deficit was $118.2 million. Management expects continued operating losses but stated existing cash and cash flows from product and service revenue should fund operating expenses, capital expenditures and debt service for at least 12 months from the filing’s financial-statement issuance date, subject to assumptions.
Changes, outlook and risks
- Q2 growth reflected higher handheld placements, including U.S. state and local demand associated with opioid-detection funding, increased desktop sales and higher service revenue. Product-and-service gross margin improved to 59% from 51% in Q2; first-half margin rose to 55% from 52%.
- Management expects continued investment in sales capacity, manufacturing and R&D, and anticipates higher public-company operating costs. The filing provides no specific revenue or earnings guidance.
- Risks include recurring losses and possible need for additional financing; long government sales cycles and customer concentration; reliance on sole-, single- or limited-source suppliers; and ongoing COVID-19-related supply, travel and customer-payment disruptions. One customer represented 19% of first-half revenue. At June 30, a $3.2 million gross receivable balance from EMEA included $1.7 million more than 90 days past due, substantially covered by an allowance.
- On August 3, 2022, the company acquired TRACE Analytics GmbH for $15.3 million upfront, plus up to $2.0 million contingent consideration. Purchase accounting was incomplete as of the filing; the company expects to integrate TRACE’s sampling technology into future products. A new North Carolina lease signed July 17 has an 88-month term and approximately $4.0 million in total lease costs.
- No material legal proceedings or material changes to previously disclosed risk factors were reported. Management concluded disclosure controls were effective at a reasonable assurance level.
Important facts for investors to verify
- Whether revenue growth and improving product-and-service margins persist as device and consumables mix, pricing and distribution channels change.
- Cash-burn trajectory, operating-expense growth and the assumptions underlying management’s stated 12-month funding outlook.
- Collection of overdue EMEA receivables and exposure to significant customers and constrained component suppliers.
- Final purchase-price allocation and contingent payments for TRACE, and the acquisition’s financial and operational contribution.
- Revolver terms, covenant compliance and liquidity after the acquisition and planned lease expansion.